Surveillance of Echinococcus granulosus in dogs with arecoline hydrobromide.
Arecoline hydrobromide has been used for almost half a century for the treatment of Echinococcus granulosus in dogs. Trials in New Zealand showed that it had real limitations for this purpose. Its main value lies in its use as a diagnostic agent for detecting infections in dogs on a group basis. The data so obtained can be used in educating dog owners as well as for providing base-line data and an index of progress in a continuing control programme. The drug's limitations for treatment and value as a diagnostic agent in a field trial are assessed.
D000818:Animals; D000871:Anthelmintics / Q000627:therapeutic use*; D001115:Arecoline / Q000627:therapeutic use*; D004283:Dog Diseases / Q000175:diagnosis / Q000188:drug therapy*; D004285:Dogs; D004443:Echinococcosis / Q000175:diagnosis / Q000188:drug therapy / Q000662:veterinary*; D005069:Evaluation Studies as Topic; D009520:New Zealand
D000871:Anthelmintics; D001115:Arecoline